Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home exercise program aims to boost Heart-Lung function in pulmonary hypertension patients

NCT ID NCT07149935

Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a long-term rehabilitation program—combining home exercise and breathing muscle training—can improve clinical outcomes and heart-lung function in people with pulmonary arterial hypertension. About 104 adults with stable disease will be randomly assigned to rehab or usual care. The main goals are to see if rehab increases walking distance and speeds up clinical improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rehabilitation training (home exercise and inspiratory muscle training)
What this could lead to
If it works, this could provide a safe, drug-free way to improve daily function and heart-lung health for people with pulmonary hypertension.
What could go wrong
This is a relatively small, early-stage study (104 participants) and the training is self-administered at home, so results may vary. It is not a cure and aims only to manage symptoms and slow progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 104 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR \> 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation. 2. Patients who are in the status of WHO-FC I-III. 3. Patients between 18 and 75 years old 4. Female subjects are not pregnant. 5. Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease). 6. Patients have not received exercise rehabilitation training within six months. Exclusion Criteria: Patients with the following diseases or symptoms: 1. Pulmonary vascular occlusive disease 2. Respiratory diseases 3. Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease 4. Active liver disease 5. Severe kidney disease 6. Motor disorders (e.g. lower limb fracture, ataxia, etc.) 7. Malignant tumour diseases 8. Physical disability 9. Hb ≤ 80g / L 10. Systolic blood pressure ≤85mmHg 11. History of syncope within 3 months 12. History of supraventricular or ventricular arrhythmia at rest within 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Renji Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 210007, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.